Metachromatic leukodystrophy

This code represents metachromatic leukodystrophy (MLD), a rare, inherited metabolic disorder characterized by the accumulation of sulfatides in the brain, spinal cord, and peripheral nerves. This accumulation leads to the progressive destruction of myelin, resulting in neurological deterioration. Patients typically experience motor, cognitive, and behavioral impairments.

Use this code for patients diagnosed with metachromatic leukodystrophy, confirmed through genetic testing, enzyme assays (arylsulfatase A deficiency), or characteristic MRI findings. Documentation should clearly indicate the diagnosis of MLD, often specifying the type (e.g., late infantile, juvenile, adult) if known, and the associated neurological manifestations.

• Ensure documentation specifies the confirmed diagnosis of metachromatic leukodystrophy, not just suspected or rule-out.
• Code any associated neurological manifestations (e.g., spasticity, ataxia, cognitive impairment) as secondary diagnoses.
• Distinguish from other leukodystrophies; this code is specific to metachromatic leukodystrophy due to arylsulfatase A deficiency.